Adicet Bio financials
$6.83+7.56%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $25.0M | $9.7M | $17.9M |
| Gross profit | $0.00 | $0.00 | $0.00 | $25.0M | $9.7M | $17.9M |
| Gross margin | — | — | — | 100.0% | 100.0% | 100.0% |
| Operating income | -$122.1M | -$127.6M | -$152.0M | -$72.6M | -$61.4M | -$39.2M |
| Net income | -$116.8M | -$117.1M | -$142.7M | -$69.8M | -$62.0M | -$36.7M |
| Net margin | — | — | — | −279.3% | −637.2% | −204.9% |
| Diluted EPS | $-16.95 | $-21.33 | $-52.96 | $-27.20 | $-32.00 | $-80.16 |
| EBITDA | -$115.7M | -$121.1M | -$126.5M | -$70.0M | -$59.7M | -$37.8M |
| Operating cash flow | -$95.2M | -$92.4M | -$93.7M | -$44.8M | -$51.1M | -$41.6M |
| Free cash flow | -$97.0M | -$93.5M | -$98.2M | -$61.5M | -$64.1M | -$42.5M |
| Diluted shares | 6.9M | 5.5M | 2.7M | 2.6M | 1.9M | 0.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $38.9M | $56.5M | $159.7M | $257.7M | $277.5M | $84.3M |
| Short-term investments | $119.6M | $119.8M | $0.00 | $0.00 | — | $10.3M |
| Total debt | $991.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $192.4M | $220.2M | $207.3M | $330.7M | $338.9M | $153.8M |
| Total liabilities | $33.1M | $33.6M | $37.1M | $38.4M | $35.8M | $44.0M |
| Shareholders' equity | $159.2M | $186.6M | $170.2M | $292.3M | $303.1M | $109.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology